James Lim, PhD, on Addressing Lingering Needs in Research Process Development and Clinical ManufacturingMay 15th 2023
The cofounder and chief scientific officer of Xcell Biosciences discussed the company’s efforts to introduce new technologies for improving cell therapy development and manufacturing.
Leticia Tordesillas, PhD, on the Potential of γδ CAR T-cells to Treat Bone Metastatic Prostate CancerApril 24th 2023
The research scientist at Moffitt Cancer Center discussed the results of the preclinical study she presented at the 2023 AACR annual meeting and avenues for further research.
Paul Stewart, PhD, on the Potential of Genetic Medicine Approaches in Squamous Cell Lung CancerApril 18th 2023
The assistant member at the Department of Biostatistics and Bioinformatics at Moffitt Cancer Center shared the potential implications of the findings he is presenting at the 2023 AACR annual meeting on proteomics and metabolomics.
Takeaways From Phase 1 Trial of RTX-240 in Solid Tumors: Alexander I. Spira, MD, PhD, FACPMay 10th 2022
Alexander I. Spira, MD, PhD, FACP, research institute director with Virginia Cancer Specialists Research Institute, discusses the examination of RTX-240 in a phase 1 trial (NCT04372706) with solid tumors, presented recently at the 2022 AACR Annual Meeting.
Exploring NG-641 Plus Nivolumab for Previously Treated Metastatic or Advanced Epithelial TumorsApril 15th 2022
Already, NG-641 has shown encouraging preliminary safety and tolerability results in the ongoing phase 1a dose-escalation STAR trial (NCT04053283), which is a first-in-human study for the gene therapy.